Download PDF
Nuklearmedizin 1979; 18(02): 86-90
DOI: 10.1055/s-0037-1620881
Originalarbeiten - Original Articles
Schattauer GmbH

Radioiodide Treatment of Pulmonary Metastases of Differentiated Thyroid Cancer

Results and Prognostic FactorsRadiojodbehandlung der Lungenmetastasen des differenzierten Schilddrüsenkrebses.Ergebnisse und prognostische Faktoren
J. Němec
1   From the Research Institute of Endocrinology, Prague, and the Department of Nuclear Medicine, Faculty Hospital, Prague-Motol, ČSSR
,
V. Zamrazil
1   From the Research Institute of Endocrinology, Prague, and the Department of Nuclear Medicine, Faculty Hospital, Prague-Motol, ČSSR
,
D. Pohunková
1   From the Research Institute of Endocrinology, Prague, and the Department of Nuclear Medicine, Faculty Hospital, Prague-Motol, ČSSR
,
S. Röhling
1   From the Research Institute of Endocrinology, Prague, and the Department of Nuclear Medicine, Faculty Hospital, Prague-Motol, ČSSR
› Author Affiliations
Further Information

Publication History

Received: 03 August 1978

Publication Date:
10 January 2018 (online)

    Permissions and Reprints

Pulmonary metastases were found in 123 out of 840 patients with thyroid cancer between 1955-1977. 87 patients with pulmonary metastases of differentiated cancer were studied in detail, including an evaluation of prognostically important factors. In 66 of them, the induction of 131I uptake in metastases was attempted, in half of them successfully. Uptake was achieved more frequently in younger subjects, in papillary cancers and in patients with fine pulmonary metastases on chest films. Survival (not corrected for age) was evaluated 10 and 15 years following the diagnosis of thyroid cancer and was found to be 29,1 % and 12,2%, respectively. Significantly higher survival rates were seen in younger patients, in patients with the fine type of pulmonary metastases, in the absence of bone metastases and, particularly, in patients with induced 131I uptake in metastases. Papillary cancers were found to have higher survival rates in males and in young subjects only, in the whole group the survival rates were independent of either microscopic type or sex. It is believed that biologic behaviour of distant (pulmonary) metastases may be influenced by radioiodide therapy.

Zwischen 1955 bis 1977 wurden in unserem Institut 840 Kranke mit Schilddrüsenkrebs behandelt; bei 123 wurden Lungenmetastasen gefunden. Von diesen wurden 87 Kranke mit Metastasen eines differenzierten Schilddrüsenkarzinomes im Hinblick auf prognostisch wichtige Faktoren eingehend beobachtet. Bei 66 Patienten versuchten wir, die Radiojodspeicherung in den Metastasen zu induzieren; bei der Hälfte davon ist dies gelungen. Bessere Erfolge erreichten wir bei jüngeren Kranken, bei papillärem Karzinom, und dort, wo es sich um kleinknotige Metastasen handelte. Die Uberlebensrate wurde 10 und 15 Jahre nach der Diagnose des Schilddrüsenkarzinomes bestimmt; sie betrug 29,1 %bzw. 12,2%. Ein signifikant höhere Uberlebensrate wurde bei jüngeren Patienten, bei kleinknotigen Metastasen, bei Kranken ohne gleichzeitig vorhandenen Knochenmetastasen und hauptsächlich dort beobachtet, wo eine Radiojodspeicherung in den Metastasen bewirkt worden war. Beim papillären Karzinom fanden wir eine höhere überlebensrate nur bei männlichen und jüngeren Kranken, aber sonst war die überlebensrate weder vom mikroskopischen Befund noch vom Geschlecht der Kranken abhängig. Wir sind der Ansicht, daß das biologische Verhalten von Fernmetastasen durch Radiojodbehandlung beeinflußt werden kann.

 

  • References

  • (1) Buckwalter JA. Prognosis of Thyroid Carcinoma. In: Thyroid Cancer (Ed. Hedinger CE), UICC Monograph 12, Springer, Berlin 1969: 313-315.
    PubMedGoogle Scholar
  • (2) Buckwalter JA, Thomas CG. Selection of surgical treatment for well differentiated thyroid carcinomas. Ann. Surg 176: 565-577 1972; .
    CrossrefPubMedGoogle Scholar
  • (3) Crile G. Endocrine dependency of papillary carcinoma of the thyroid. J. Amer. med. Ass 195: 721-724 1966; .
    CrossrefGoogle Scholar
  • (4) Crile G. Changing end-results in patients with papillary carcinoma of the thyroid. Surg. Gynecol. Obstet 132: 460-468 1971; .
    PubMedGoogle Scholar
  • (5) Doll R. Summarizing Statement on Results of Treatment. In: Thyroid Cancer (Ed. Hedinger CE), UICC Monograph 12, Springer, Berlin 1969: 309-312.
    PubMedGoogle Scholar
  • (6) Fransilla K. Value of histologic classification of thyroid cancer. Acta pathol. microbiol. scand. Sect. A., Suppl 225: 1-76 1971; .
    Google Scholar
  • (7) Fransilla K. Is the differentiation between papillary and follicular carcinoma valid?. Cancer 32: 853-864 1973; .
    CrossrefPubMedGoogle Scholar
  • (8) Krishnamurthy GT, Blahd WH. Radioiodine 1-131 therapy in the management of thyroid cancer. A prospective study. Cancer 40: 195-202 1977; .
    PubMedGoogle Scholar
  • (9) Némec J, Pohunková D, Zamrazil V, Rohling S, Zeman V. Pulmonary metastases in thyroid cancer. To be published.
    Google Scholar
  • (10) Nèmec J, Rohling S, Zamrazil V, Pohunková D. Comparison of the distribution of diagnostic and thyroablative amounts of 131-1 in the evaluation of differentiated thyroid cancers. J. nucl. Med.,. in press.
    Google Scholar
  • (11) Némec J, Zamrazil V, Pohunková D, Rohling S, Holik F, Zeman V. X-Ray character of pulmonary metastases of thyroid cancer. To be published.
    Google Scholar
  • (12) Tubiana M, Lacour J, Monnier JP, Bergiron C, Rérard-Marchand G, Roujeau J, Parmentier C. External radiotherapy and radioiodine in the treatment of 359 thyroid cancers. Brit. J. Radiol 48: 894-907 1975; .
    CrossrefPubMedGoogle Scholar
  • (13) VanHerle AJ, Uller RP. Thyroid cancer classification, clinical features and therapy. Pharmac. Ther. C 2: 215-238 1977; .
    Google Scholar